RecruitingEarly Phase IFemale onlyEN originalBreast cancerMetastatic / advanced

A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The goal of this study is to test whether monitoring insulin levels and using pioglitazone to treat hyperglycemia and hyperinsulinemia in patients treated with Alpelisib for metastatic breast cancer is feasible and safe, and to assess the rates of glycemic control, dose reductions and treatment discontinuation and the progression free survival of patients treated with this regimen.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Rak piersi z przerzutami, dodatni na receptor estrogenowy, ujemny na HER2, z mutacją PIK3CA, przygotowany do leczenia Alpelisibem i fulwestrantem
  • Wiek 18-85 lat
  • Ogólny stan zdrowia pozwalający na codzienne aktywności (stopień 0-2)
  • Zdolność do zrozumienia informacji i chęć podpisania zgody na udział w badaniu

✗ Disqualifies

  • Zaburzenia lub choroby przewodu pokarmowego mogące wpłynąć na wchłanianie leku
  • Niekontrolowana cukrzyca (HbA1c powyżej 8%)
  • Cukrzyca leczona insuliną
  • Inne niekontrolowane choroby, w tym aktywne infekcje, problemy sercowe lub poważne problemy psychiczne
  • Ciąża
  • Uczulenie na pioglitazon

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Maximum age
85 Years
Last updated (source)
March 3, 2023
Sex
Female only

Therapies / drugs in trial

Locations (1)

Rambam Health Care Campus

Haifa, Israel

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.